Source comparison
BPC-157 Research Menopause Considerations: Study Design Comparison
Ovariectomized rats (wound healing) Wound closure rate, capillary density 10 mcg/kg subcutaneous daily 14 days 40% faster closure vs control, increased VEGF expression Short duration. Doesn't model chronic post-menopausal state Ovariectomized rats (fracture re
This comparison does not assign a generated winner or score.
- Ovariectomized rats (wound healing)
- Wound closure rate, capillary density
- 10 mcg/kg subcutaneous daily
- 14 days
- 40% faster closure vs control, increased VEGF expression
- Short duration. Doesn't model chronic post-menopausal state
- Ovariectomized rats (fracture repair)
- Trabecular bone volume, healing time
- 10 mcg/kg intraperitoneal daily
- 28 days
- 28% faster healing, increased bone volume at fracture site
- Fracture model only. No data on systemic bone density maintenance
- In vitro tendon fibroblasts
- Collagen I/III gene expression
- 1–10 ng/mL culture concentration
- 72 hours
- Dose-dependent increase in collagen synthesis markers
- No in vivo validation in estrogen-depleted model
- Ovariectomized rats (gastric ulcer)
- Ulcer area reduction, mucosal thickness
- 10 mcg/kg oral or subcutaneous
- 7 days
- 60% ulcer area reduction vs saline control
- Acute injury model. Unclear relevance to chronic menopausal GI symptoms
- Professional Assessment
- The ovariectomy model is standard for preclinical menopause research, but the absence of long-term (6+ month) dosing studies leaves chronic safety and efficacy in true post-menopausal tissue environments unvalidated. Human trials are essential before any clinical recommendation.